Cellceutix Corp. (CTIX.OB) Announces Completion of All Three Animal Safety Pharmacology Studies Required by FDA Prior to Filing Investigational New Drug (IND) Application
Cellceutix Corp. announced earlier this morning that it has completed all three animal safety pharmacology studies for its cancer compound, Kevetrin™, that are required by the U. S. Food and Drug Administration prior to filing an IND. These studies evaluate the impact of the administration of a compound on the respiratory, cardiovascular, and central nervous systems. Dr. Krishna Menon, Chief Scientific Officer of Cellceutix, commented, "Previous required testing on the respiratory and central nervous systems showed no significant neuropharmacological or biologically relevant effects. This set of cardiovascular testing coincided with those results with no significant effects at low, medium or…